The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.
Clinical diagnosis of mild cognitive impairment (MCI).
Clinical diagnosis of Alzheimer's Disease.
MCI and AD patients with hyperglycemia ( Fasting glucose >=100 mg/dL).
MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).
Cancer patients.
Severe heart, lung, liver, and kidney diseases.
Severe disability or aphasia.
Malnutrition (body weight changes > 5% within one month).
Chung Shan Medical University
Lead sponsor
National Science and Technology Council
Collaborator